annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 11G Prognostic value of biomarkers in tissue microarrays (TMAs) of squamous
cell carcinomas of the oral tongue (SCCOT). (Abstract #5548)
W. N. William Junior, M. Nunez, X. Gu, R. W. Jacobs, A. M. Litvak, C. R. Pickering,
J. Lee, A. K. El-Naggar, B. S. Glisson, J. Myers
Brd. 11H Evaluation of ALDH1-A1 as a biomarker for metastasis of head and neck
cancer. (Abstract #5549)
Z. G. Chen, S. Nannapaneni, S. Muller, N. F. Saba, M. Tighiouart, L. Pan,
D. M. Shin
Brd. 12A The prognostic value of STAT3 protein in patients with head and neck
squamous cell carcinoma (HNSCC) harboring PTEN loss. (Abstract #5550)
G. Fountzilas, E. Pectasides, P. Kountourakis, P. Gouveris, C. Sasaki, D. Duffey,
D. G. Pectasides, D. Rimm, B. Burtness, D. Psyrri
Brd. 12B Expression of drug-resistance-related proteins in nasopharyngeal cancer
(NPC) patients treated with cisplatin-based concurrent chemoradiotherapy.
(Abstract #5551)
Y. Hwang, H. Lee, J. Jeong, S. Kang, M. Ahn, J. Han, J. Kim, C. Kim, J. Choi
Brd. 12F Association of high Gli1 expression with poor survival in head and neck
cancer patients treated with radiation therapy (RTOG 9003). (Abstract #5552)
C. H. Chung, J. Dignam, M. E. Hammond, A. M. Magliocco, R. Jordan, A. Trotti,
S. Spencer, J. S. Cooper, Q. Le, K. Ang
Brd. 12G Prospective phase II study of tumor response assessment by CT and
FDG-PET/CT following 8 weekly doses of cetuximab in patients with
metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
(Abstract #5553)
J. Ley, D. Adkins, D.I. Kuperman, B.A. Siegel, F. Dehdashti, F. Wippold,
K. Trinkaus, J. Subramanian, T. Rachocki
Brd. 12H A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with
recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
(Abstract #5554)
D. G. Pfister, S. Haque, H. Stambuk, D. M. Lisa, R. Shen, D. Carlson, M. G. Fury
Brd. 13A A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX)
combination in patients with recurrent or metastatic squamous cell
carcinoma of the head and neck (SCCHN): A Southwest Oncology Group
study. (Abstract #5555)
K. E. Bickel, F. P. Worden, J. Moon, O. Kucuk, R. H. Wheeler, J. Clark, G. T. Wolf,
S. Urba
Brd. 13B A phase II study of GW786034 (pazopanib) in Asian patients with
recurrent/metastatic undifferentiated nasopharyngeal carcinoma. (Abstract
#5556)
W. T. Lim, C. Thng, C. K. Toh, B. Chowbay, B. C. Goh, S. Leong, S. P. Ivy, Q. Ng,
D. S. Tan, E. Tan
Brd. 13C Efficacy of combining targeted therapies cetuximab and dasatinib for
resistant salivary gland carcinomas in vitro. (Abstract #5557)
A. Brohl, K. Steadman, B. Kallakury, J. F. Deeken
Brd. 13D Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition
in a direct patient tumor model (DPTM) of head and neck squamous cell
cancer (HNSCC). (Abstract #5558)
S. Keysar, R. Anderson, S. Takimoto, A. Tan, I. Deyneko, K. McGovern,
R. W. Ross, J. Song, A. Jimeno
Brd. 13E Activity of novel RET inhibitors against RET genotypes associated with
medullary thyroid cancer. (Abstract #5559)
A. W. Gramza, J. Patterson, J. Peters, M. Kaufman, S. Wise, D. Flynn
Brd. 13F Mature results of a phase I trial of bortezomib, cisplatin, and radiotherapy for
advanced or recurrent head and neck cancer. (Abstract #5560)
R. S. Axelrod, P. H. Ahn, G. J. Kubicek, P. R. Anne, D. Cognetti, A. Dicker,
M. Machtay
203
SUNDAY